CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 55 enrolled
Drug / intervention
PET-based, dose-painted, accelerated chemoradiotherapy +1 morecombination
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03481114
NCT03481114Phase 2Completed
CompareCT.gov

Patient-Reported Outcomes Following Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer: A Randomized Trial Comparing Two Radiotherapy Schedules

Albert Einstein College of Medicine·interventional·Posted Mar 29, 2018·Updated Apr 22, 2026

In Brief

A Phase 2 clinical trial evaluating PET-based, dose-painted, accelerated chemoradiotherapy and Standard chemoradiotherapy for Non-small Cell Lung Cancer. Completed, enrolled 55 participants across 1 site.

Detailed Summary

The primary objective of this study is to evaluate patient-reported outcomes during and after concurrent chemoradiotherapy for locally-advanced non-small cell lung cancer. Patients will be randomized to a standard 6-week radiotherapy course or a 4-week radiotherapy course using dose-painting based on pre-treatment Positron Emission Tomography (PET) findings.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-small Cell Lung Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedMar 29, 2018
Enrollment StartAug 28, 2017
Primary CompletionDec 27, 2023
TodayJul 2, 2026
Enrollment to primary: 6.3 yearsPosted 8.3 years ago

Interventions

PET-based, dose-painted, accelerated chemoradiotherapycombination

Patients in this arm will receive a more personalized and shorter radiation therapy treatment course utilizing PET imaging.

Standard chemoradiotherapycombination

Patients in this arm will receive a standard radiotherapy course.